国际专家共识:循环肿瘤细胞在实体瘤中的临床整合
共识确认CTC在转移性乳腺癌和前列腺癌的预后与治疗监测中有临床效用,包括转移性去势抵抗性前列腺癌的AR-V7检测用于治疗选择;其他肿瘤中CTC仍处于研究阶段。专家强调从计数向表型与分子特征转变,并倡导CTC与cfDNA整合的液体活检方法。
要点
- CTC在转移性乳腺癌和前列腺癌的预后与治疗监测中获共识,含mCRPC的AR-V7检测。
- 其他肿瘤中CTC仍属研究性,早期乳腺癌联合cfDNA检测微小残留病灶有前景。
- CellSearch®是目前唯一具有高级别临床使用证据的平台。
核心结论
- 共识为CTC的临床整合提供实践指导,并列出释放其精准肿瘤学潜力的研究优先方向。
研究设计与样本
- 11位CTC专家确定争议领域,结构化问卷发放给55位国际多学科专家,共识阈值预设为≥70%同意。
主要发现
- 共识确认CTC在转移性乳腺癌和前列腺癌的预后与治疗监测中有临床效用,包括mCRPC的AR-V7检测用于治疗选择。
- 其他肿瘤中CTC仍为研究性;早期疾病临床效用未确立,但早期乳腺癌联合cfDNA检测微小残留病灶有前景。
- CellSearch®是目前唯一具有高级别临床使用证据的平台,新兴技术有前景。
关键数值与推荐
- 共识定义为≥70%同意。
临床怎么用
- 转移性乳腺癌和前列腺癌可利用CTC进行预后评估与治疗监测,mCRPC可检测AR-V7指导治疗选择。
- 早期乳腺癌可探索CTC联合cfDNA检测微小残留病灶,其他瘤种建议在研究框架内使用。
- 临床使用优先选择有高级别证据的CellSearch®平台。
局限性
- 临床采用受限主要因缺乏共识与标准化技术。
- 关键挑战包括提高检测灵敏度/特异性、标准化工作流程、生成稳健数据和临床医生教育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circulating tumor cells (CTCs) are a versatile biomarker in solid tumors. Extensive research supports their clinical relevance and led to regulatory approval in breast, prostate, and colorectal cancers. However, clinical adoption remains limited mainly due to the lack of consensus and standardized technologies. Additionally, CTC research lacks unified direction. To address these gaps, an international expert panel was established to assess the current and future clinical utility of CTCs. METHODS: A panel of 11 CTC experts identified key areas of controversy, informing a structured survey distributed to 55 international multidisciplinary experts. Consensus was predefined as ≥ 70 % agreement. Areas without consensus were discussed in a virtual meeting, leading to final statements on the clinical integration of CTCs. RESULTS: Thirty-seven experts completed the survey. Consensus was reached on the clinical utility of CTCs for prognosis and treatment monitoring in metastatic breast (BC) and prostate (PC) cancers, including AR-V7 testing in metastatic castration-resistant PC for therapy selection. In other tumors, CTCs remain investigational. Experts agreed that while clinical utility is not yet established in early-stage disease, CTCs show promise in early BC, especially combined with cell-free DNA (cfDNA) for minimal residual disease detection. CellSearch® is currently the only platform with high-level evidence for clinical use, though emerging technologies are promising. Key challenges include improving detection sensitivity/specificity, standardizing workflows, generating robust data, and clinician education. Experts emphasized shifting from enumeration to phenotypic and molecular characterization, particularly for treatment guidance, and highlighted the complementary role of CTCs and cfDNA, advocating for integrated liquid biopsy approaches. CONCLUSIONS: This consensus offers practical guidance for clinical integration of CTCs and outlines strategic research priorities to unlock their full potential in precision oncology.
引用
- Nicolò E, Reduzzi C, Pierga JY, et al. International expert consensus on the clinical integration of circulating tumor cells in solid tumors. Eur J Cancer. 2025. PMID: 41172567. doi:10.1016/j.ejca.2025.116050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。